Atomwise has forged fifteen research collaborations with universities globally to develop broad-spectrum treatments for Covid-19, as well as other coronaviruses.
While drug repurposing may enable a quicker response to the current outbreak, its long-term use may be limited due to mutations and evolution of the virus, noted the company.
Atomwise and its collaborators will leverage the company’s predictive models and artificial intelligence (AI) technology to potentially increase the ‘probability of success for future therapies’.
Last September, Atomwise signed four deals for AI-based drug discovery. Our parent business intelligence company Each collaborative project focuses on the development of drug candidates that demonstrate